版本:
中国

BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN

June 19 Exelixis Inc

* Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

* Exelixis inc - u.s. Regulatory submission remains on track for q3'17

* Exelixis - cabozantinib demonstrated clinically meaningful,statistically significant reduction in rate of disease progression or death as measured by pfs Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐